Journey Medical’s (DERM) “Buy” Rating Reiterated at B. Riley Financial

B. Riley Financial reissued their buy rating on shares of Journey Medical (NASDAQ:DERM) in a research report report published on Thursday, Marketbeat.com reports. B. Riley Financial currently has a $15.00 target price on the stock, up from their previous target price of $12.00.

Several other equities research analysts also recently issued reports on the company. Wall Street Zen upgraded Journey Medical from a “hold” rating to a “buy” rating in a report on Saturday, June 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Journey Medical in a research report on Friday, July 17th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $14.00.

Journey Medical Stock Up 1.1%

Shares of NASDAQ DERM opened at $6.72 on Thursday. The firm has a market cap of $185.00 million, a price-to-earnings ratio of -30.55 and a beta of 1.08. The company has a quick ratio of 1.47, a current ratio of 1.59 and a debt-to-equity ratio of 0.64. Journey Medical has a 52-week low of $4.31 and a 52-week high of $9.56. The business’s 50 day moving average is $6.61 and its two-hundred day moving average is $6.61.

Journey Medical (NASDAQ:DERM) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.01) EPS for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.01. Journey Medical had a negative return on equity of 20.23% and a negative net margin of 8.95%.The company had revenue of $18.51 million for the quarter, compared to analysts’ expectations of $18.36 million. Research analysts predict that Journey Medical will post -0.02 EPS for the current year.

Hedge Funds Weigh In On Journey Medical

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. J. Goldman & Co LP acquired a new position in shares of Journey Medical in the second quarter worth $974,000. ADAR1 Capital Management LLC acquired a new stake in shares of Journey Medical in the second quarter valued at $280,000. BlackRock Inc. purchased a new position in Journey Medical in the second quarter valued at $715,000. Persistent Asset Partners Ltd purchased a new position in Journey Medical in the second quarter valued at $71,000. Finally, Walleye Capital LLC acquired a new position in Journey Medical during the 2nd quarter worth $463,000. Hedge funds and other institutional investors own 7.25% of the company’s stock.

Journey Medical News Summary

Here are the key news stories impacting Journey Medical this week:

• Positive Sentiment: Emrosi momentum remains strong: Journey Medical said Emrosi revenue reached $8.1 million, with sales rising 20% sequentially. Management also highlighted 38% high-quality insurance coverage and indicated that average selling price gains could continue in the second half of 2026, supporting growth and profitability. Journey Medical signals continued ASP gains in 2H 2026
• Positive Sentiment: Analyst price target raised: B. Riley reaffirmed its “Buy” rating and increased its price target to $15 from $12, implying substantial potential upside from recent trading levels. B. Riley rating and price target report
• Positive Sentiment: Second-quarter results exceeded expectations: Journey Medical reported adjusted earnings of a $0.01-per-share loss, ahead of the $0.02 loss analysts expected, while revenue of $18.51 million topped the $18.36 million consensus estimate. The results and Emrosi growth reinforce the company’s near-term operating momentum. Journey Medical second-quarter 2026 results
• Negative Sentiment: HC Wainwright lowered multiple earnings forecasts: The firm reduced its 2026 third- and fourth-quarter EPS estimates to $0.01 and $0.02, respectively, and cut its FY2027-FY2030 forecasts. The revisions suggest analysts expect a slower earnings ramp than previously projected, despite maintaining a $0.17 current-year consensus estimate. Journey Medical earnings estimate revisions

About Journey Medical

Journey Medical Corp, headquartered in Fairfield, New Jersey, is a commercial dermatology company focused on acquiring, developing and marketing prescription dermatology products in the United States. Since its incorporation in 2019, the company has built a portfolio of both branded and generic topical therapies designed to address a range of skin conditions, including acne, atopic dermatitis, fungal infections and inflammatory lesions.

The company’s product lineup features antibiotic/anti-inflammatory combinations and corticosteroid-based formulations delivered through proprietary gel, cream and foam vehicles.